Simvastatin is metabolised through the CYP3A4 pathway. Concomitant use of CYP3A4 inhibitors has the potential to increase exposure to simvastatin 1. Both amlodipine and diltiazem are substrates Conclusions . The MHRA . Drug Safety Update highlights changes to the simvastatin SmPC regarding...